PubMed Health⌕ Search

SEARCH · PubMed Health

Results for “Intractable Pain”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 595 records · Page 33Linked to original sources

Intraventricular morphine for intractable craniofacial pain.

This case management report on a patient with advanced craniofacial neoplasm discusses the successful treatment of chronic pain by the cortical intraventricular narcotic administration. A previously treated patient with surgery and radiotherapy for carcinoma of the palate developed severe intractable pain despite high dose oral morphine therapy. Investigations revealed that neoplasm had reoccurred with extensive infiltration. Intraventricular morphine therapy was discussed and accepted by the patient and family. A ventricular shunt with an Ommaya reservoir was inserted under local anaesthesia. Preservative-free morphine sulphate in increasing doses of 0.25 to 1 mg was administered, once daily, which kept the patient in a pain-free state. The treatment was initiated in the hospital and continued at home till the demise of the patient on the 9th week. The home care was provided by the nurses of Home Nursing Foundation and Singapore Cancer Society under physician supervision. There were no complications which had been reported in the literature, observed in the management of this patient.

Drug Administration Schedule↗

Intractable neck pain.

A retrospective survey of 1,661 patients seen over a 10-year period at a pain clinic yielded 55 patients with intractable neck pain as the presenting complaint. In 89% there was an industrial or motor vehicle accident as the precipitating event, 78% were involved in legal proceedings relating to the accident, and in 87% the pain radiated to neighboring structures. Diagnostically, 36% had no physical signs, and cervical radiographs were normal for 46%. There was a high incidence of previous psychiatric treatment (53%) and major intrafamily problems (60%). Treatment mainly by psychotherapy or tricyclic antidepressants resulted in some benefit for 56% of patients. Legal compensation and change in occupation were not major factors influencing the outcome of treatment.

Accidents, Occupational↗

Endoscopic section of the sensory trigeminal root, the glossopharyngeal nerve, and the cranial part of the vagus for intractable facial pain caused by upper jaw carcinoma.

In a patient with intractable facial pain caused by a deep-seated carcinoma of the upper jaw, relief was obtained following endoscopic section of the sensory trigeminal root, the glossopharyngeal nerve, and the cranial part of the vagus. Previous stereotactic thalamotomy had failed. The endoscopic method is briefly described and discussed.

Cerebellopontine Angle↗

The use of standard imaging techniques and their diagnostic value in the workup of renal colic in the setting of intractable flank pain.

OBJECTIVES: This study reviews the rate at which diagnostic imaging techniques are used in patients with intractable flank pain attributed to renal colic who are admitted to the hospital through the emergency room and determines the diagnostic values of plain film of the abdomen {kidney, ureter, bladder [KUB]} and of ultrasonography (US) of the urinary tract, using intravenous urography (IVU) as the gold standard for establishing the presence of a calculus. METHODS: We reviewed the medical records of 288 patients who were admitted to our medical center over a period of 5 consecutive years for intractable flank pain, the admission and working diagnosis in all cases being that of renal colic, and we retrieved all data pertaining to their diagnostic evaluation. RESULTS: A total of 265 patients (92%) were subjected to KUB, 158 (55%) to IVU, and 135 (45%) to US of the renal-urinary tract. Two diagnostic imaging techniques were used in the same patient in the following combinations: KUB and IVU in 146 patients (51%), KUB and US in 110 (38%), and IVU and US in 60 (21%). Three imaging techniques (IVU, KUB, and US) were utilized in 54 patients (19%). The sensitivity and specificity of KUB alone were 95% and 65%, respectively, and the positive and negative predictive values were 82% and 88%. The sensitivity of US alone was 93%, its specificity 83%, the positive predictive value 93%, and the negative predictive value 83%. The sensitivity of combined KUB and US (requiring both tests to be positive for diagnosing the presence of a calculus) was 89%, the specificity 100%, the positive predictive value 100%, and the negative predictive value 81%. CONCLUSIONS: Our data indicate that combining US with KUB provides the best diagnostic algorithm that approaches the yield of IVU in excluding the presence of a calculus in the renal-urinary tract in patients who present with intractable flank pain.

Algorithms↗

CT-guided stereotactic antero-medial pulvinotomy and centromedian-parafascicular thalamotomy for intractable malignant pain.

A quick and safe CT image-guided stereotactic thalamotomy technique that has proved ideal for alleviating medically refractory intractable pain due to malignant disease is described. A simple method of deriving cartesian coordinates for target points that facilitates functional neurosurgery using CT images and the Brown-Roberts-Wells stereotactic system is also described.

Aged↗

Intractable foot pain following frostbite: case report.

This report describes a patient with intractable foot pain following frostbite in 1945. The patient continued to have progressively worsening foot pain, which eventually resulted in his losing his job and becoming wheelchair-bound. A combination of transcutaneous nerve stimulator, patellar, tendon weight-bearing/ankle foot orthoses (PTB/AFO), and crutches resulted in pain relief and good ambulatory status. A review of the literature regarding possible pathophysiology is made.

Crutches↗

[Management of intractable cancer pain: from intrathecal morphine to cell allograft].

The durable effectiveness of intrathecal morphine administration is well established for the management of intractable cancer pain, after failure of systemic opioids, secondary to the persistence of non-reversible undesirable side effects. Many patients are referred to late in the disease course. This conservative method to control pain of malignant origin must not be reserved for last resort treatment for terminal patients. Intra-cerebro-ventricular morphine administration is a very effective and generally safe method for controlling intractable cancer pain. Because of the chronic implantation of an intra-ventricular catheter this method is somewhat invasive. Its indications remain a simple and effective alternative when the topography of nociceptive pain is diffuse or cephalic. In clinical practice, intrathecal and/or intra-cerebro-ventricular administration of opioids is limited by cost, the need for specialized maintenance and mechanical malfunctions if implantable drug delivery systems, or by the risk of bacterial contamination and ambulatory constraints when repeated daily injections via an intrathecal access port are used. To answer these limitations, cell therapy using intrathecal chromaffin cell allograft is a promising approach for the management of cancer pain refractory to traditional drug therapy and pain lesion surgery. The basic rationale and preclinical studies on experimental pain models have enabled starting prospective clinical trials. Prior to transplantation, handling and preparation of the chromaffin tissue is critical for allograft viability. The initial results of clinical trials with human chromaffin cell grafts from intractable cancer pain have reported long-lasting pain relief, in correlation with met-enkephalin release into the CSF. Convincing evidence will require controlled studies. The limitations of this innovative cell therapy and especially the lack of human adrenal gland availability point to the need for new sources of cells. Perspectives include xenogenic or engineered cell lines.

Analgesics, Opioid↗

Chronic, intractable, benign pain: a syndrome and its treatment with intensive short-term group psychotherapy.

There is sufficient reason to classify some ongoing pain problems as syndromes. Patients who suffer with chronic, intractable, benign pain syndromes (CIBPS) have truly functional biopsychosocial disorders. There is no longer any current pathophysiology operative, and the pain syndrome persists with its psychosocially perpetuating and disrupting features. An intense group psychotherapy approach in the therapeutic milieu of a medical-surgical setting fosters and evokes affect expression and understanding. This encourages the formation of cognitive patterns that are therapeutically useful in that they extend coping abilities and, hence, diminish the pain and suffering experience and life problems attendant to it.

Chronic Disease↗

Epidural clonidine analgesia for intractable cancer pain: phase I.

Intrathecally administered clonidine has been reported to produce analgesia in cancer patients tolerant to intrathecal opiates. To assess the efficacy, safety, and appropriate dose of epidurally administered clonidine for the treatment of cancer pain, clonidine (range, 100-900 micrograms in 100-micrograms increments) was injected in nine patients with severe, intractable cancer pain. Clonidine produced analgesia, as measured by change in verbal pain scores, lasting more than 6 h. Clonidine also decreased blood pressure, although this effect was well tolerated and no patient met criteria for receiving iv ephedrine (greater than 30% decrease in mean arterial pressure not responsive to 500 ml iv crystalloid infusion). Clonidine decreased heart rate 10-30% and produced transient sedation. Serum glucose and cortisol and oxyhemoglobin saturation were not altered by clonidine. Clonidine was absorbed in a dose-dependent manner into the systemic circulation, although absorption and elimination kinetics were highly variable. Following study seven patients received epidural clonidine/morphine infusions at home for periods of up to 5 months with sustained analgesia. These results suggest that epidurally administered clonidine may offer effective analgesia in patients with severe, intractable cancer pain.

Analgesia, Epidural↗

Transplantation of human chromaffin cells for control of intractable cancer pain.

Adrenal medullary chromaffin cells produce high levels of endogenous opioid peptides. Recent data suggest that transplantation injected locally into the spinal subarachnoid space reduced intractable malignant pain. In order to determine the feasibility, the efficacy and the risks of using adrenal medullary tissue for control of irreducible pain, we have developed a transplantation protocol on cancer pain patients selected when they required chronic intrathecal injection of morphine and progressively increasing doses to maintain the level of analgesic effects. At the present time, our clinical trial involves 8 patients. We report here our initial results (mean follow-up: 5 months). The various data collected before and after the intrathecal administration of chromaffin cells included: 1) Pain evaluation over time, with concomitant narcotic intake, 2) CSF sampling through an implanted access port to determine the following biological parameters: biochemical assay for opioid peptides, cell count and phenotyping of lymphocytes, 3) peripheral blood samples for lymphocyte typing. The results confirm the efficacy of adrenal medullary transplantation into spinal CSF for controlling irreducible cancer pain. Complementary intrathecal and oral morphine were totally stopped in 2 cases and stabilized in 5 others. It seems essential to have an important volume of grafted tissue to achieve analgesia with high levels of metenkephalin in CSF. A progressive decrease in metenkephalin release was observed from 2 to 4 months after the transplantation. Two patients with a long-term follow-up (8 and 12 months) needed another intrathecal chromaffin cell graft.

Adrenal Medulla↗

Treatment of intractable cancer pain by electronically controlled parenteral infusion of analgesic drugs.

Intractable metastatic cancer pain can be controlled in the majority of cases with narcotic drugs. This review focuses on parenteral analgesic therapy; the available drugs, administration systems, and electronic infusion devices. The range of drugs suitable for parenteral therapy, including continuous infusion therapy by subcutaneous, intravenous, or epidural routes is limited both by pharmacokinetic and side effects profiles. Implantable ports and catheter systems permit ambulatory delivery of drugs when combined with portable electronic pumps. This enables patient care to move from a bed-bound hospital therapy to ambulation in the hospital or home. The safeguards, features, and modes of operation of these pump-port-catheter-drug systems are described.

Analgesics↗

Clinical evaluation of transhiatal bilateral splanchnicotomy for patients with intractable supramesenteric pain.

Although a transhiatal bilateral splanchnicotomy (TBS) has many advantages, it has not been widely employed as an effective minimal invasive therapy for intractable supramesenteric pain. Furthermore, the effects of TBS have not yet been clearly evaluated. Between 1995 and 1997, TBS was performed on 11 patients with intractable epigastric and/or flank pain due to unresectable pancreatic cancer, chronic pancreatitis, or an unknown cause. The effect of TBS on the pain was evaluated using a novel simple pain score and pain reduction percentage scaled on the basis of the medication and the judgments by patients themselves, respectively. The detection and cutting of the bilateral great splanchnic nerves were easily performed in all of the patients using common flexible chondrocostal retractors. The evaluation of the TBS effect using the pain score clearly demonstrated the early and late mean postoperative pain score (1.1 +/- 0.9 and 1.4 +/- 1.2: mean +/- SD) to be significantly (P = 0.0002 and P = 0.002, respectively) lower than the preoperative pain score (3.5 +/- 0.7). Furthermore, the mean postoperative pain reduction percentage (85% +/- 13%) evaluated by those patients was also significantly different (P < 0.0001). The present study showed no significant complications for TBS, except for minor complications such as the transient fall of blood pressure and reparable pleural damage. Interestingly, a long-term follow-up revealed that no complications related to the splanchnicotomy were observed. These results indicate that TBS is a useful treatment for patients with intractable supramesenteric pain caused by cancer as well as benign diseases.

Abdominal Pain↗

Sacral nerve stimulation in patients with chronic intractable pelvic pain.

PURPOSE: Transforamenal sacral nerve stimulation with an implantable neuroprosthetic device has been shown to benefit patients with chronic voiding dysfunction. In this study we measured the effectiveness of sacral nerve stimulation in 10 patients with chronic intractable pelvic pain. MATERIALS AND METHODS: After successful percutaneous trial stimulation, a neuroprosthetic sacral nerve stimulation device was surgically implanted in 10 patients with chronic intractable pelvic pain. Leads were placed in the S3 and S4 foramen in 8 and 2 cases, respectively. Patients were evaluated throughout the study using a patient pain assessment questionnaire on a scale of 0-absent to 5-excruciating pain. Pain was assessed at baseline, during test stimulation, and 1, 3 and 6 months after surgical lead implantation. An additional long-term assessment was done at a median followup of 19 months. RESULTS: Of the 10 patients with the implant 9 had a decrease in the severity of the worst pain compared to baseline at a median followup of 19 months. The number of hours of pain decreased from 13.1 to 6.9 at the same followup interval. There was also an average decrease in the rate of pain from 9.7 at baseline to 4.4 on a scale of 10-always to 0-never having pain. At a median of 19 months 6 of 10 patients reported significant improvement in pelvic pain symptomology. CONCLUSIONS: These data imply that transforamenal sacral nerve stimulation can have beneficial effects on the severity and frequency of chronic intractable pelvic pain. Future clinical studies are necessary to determine the long-term effectiveness of this therapy.

Adult↗

Intrathecal octreotide for relief of intractable nonmalignant pain: 5-year experience with two cases.

Somatostatin is distributed in the substantia gelatinosa in the dorsal horn of the spinal cord, and its application has been found to produce an inhibitory effect on nociceptive neurons. Although intraspinal administration of somatostatin-14 produces pain relief in patients with cancer and in postoperative patients, its short half-life limits its clinical usefulness. Octreotide, a synthetic analog of somatostatin, is more stable and not been associated with neurodegenerative changes when administered intrathecally in dogs. Intrathecal octreotide provides analgesia without adverse drug effects when administered chronically for cancer pain; however, treatment periods have been limited. This article describes the 5-year clinical course of two patients receiving intrathecal octreotide for severe, intractable nonmalignant pain. Included in this description are the results of blinded, randomized "N of 1" trials conducted in each of these patients.

Adult↗

Arterial infusion of nitrogen mustard in the treatment of intractable pelvic pain of malignant origin.

Sixty-two patients with intractable pelvic pain secondary to malignancy arising in the pelvis received a total of 72 percutaneous retrograde arterial infusions with nitrogen mustard. Fifty-three (74%) injections resulted in marked relief of pain for an average period of six to eight weeks. Five (7%) produced no pain relief. Toxicity was mild. There were two severe complications and no deaths related to the procedure or the drug in this study. Percutaneous retrograde arterial infusion with nitrogen mustard is suggested as the preferred procedure in the attempt to control pelvic pain caused by malignancy, before resorting to spinal cordotomy or intrathecal alcohol injection.

Angiography↗

A review of intractable facial pain secondary to underlying lung neoplasms.

We describe a 63-year-old smoker who suffered from intractable facial pain secondary to an underlying lung neoplasm. Data from 30 previously reported and similar cases are also summarized. The clinical triad of a smoker suffering from periauricular pain and an elevated ESR should alert the clinician to the possibility of an occult lung mass. In these cases a computed tomography of the chest should always be obtained. Previously refractory pain typically responds to surgical resection of the mass and/or radiation therapy.

Carcinoma, Non-Small-Cell Lung↗

Insertion of intradermal needles into painful points provides analgesia for intractable abdominal scar pain.

BACKGROUND AND OBJECTIVES: Conventional treatments are often ineffective for patients having painful abdominal scars. There are painful points in and around scar tissue. We tested the hypothesis that insertion of intradermal needles into these painful points reduces scar pain. METHODS: Patients with abdominal scar pain with painful points that is not relieved by conventional treatments were allocated to a treatment group (n = 23), a sham-treatment group (n = 23), or a control group (n = 24). In the treatment group, intradermal needles were inserted into painful points detected by a pressure threshold meter (pain < or = 2.5 kg/cm(2)). In the sham-treatment group, the same needles were inserted into nonpainful points. The needles were kept in place for 24 hours. This process was repeated 20 times over a 4-week period. Responses were evaluated before and at the end of treatment, and 4 and 26 weeks after the treatment. Continuous and lancinating pain was evaluated on a 10-cm visual analog scale. We measured the area of pain and the pressure required to initiate painful-point pain. All patients took diclofenac as needed and completed a diary of daily diclofenac consumption. RESULTS: Patients in the treatment group showed a marked reduction in all pain parameters (>70%). In contrast, analgesia was minimal in the other groups. The decreases in the pain threshold pressure correlated with the decreases in continuous and lancinating pain (r =.57 and r =.63, respectively). CONCLUSION: Our data suggest that insertion of intradermal needles into painful points is a remarkably effective treatment for intractable abdominal scar pain. Analgesia presumably results from inactivation of painful points, through a yet to be elucidated mechanism.

Abdomen↗